Investment
Features
FeesSafety
Academy
More
Pluang+

Compare United States Brent Oil Fund LP (BNO) vs Pfizer Inc (PFE) Price & Performance

United States Brent Oil Fund LPTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

United States Brent Oil Fund LP vs Pfizer Inc — how do they compare? United States Brent Oil Fund LP trades at $51.1, while Pfizer Inc trades at $26.63 (market cap $154.18B). The key difference: Pfizer Inc pays a 6.36% dividend while United States Brent Oil Fund LP pays none, and United States Brent Oil Fund LP is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.

BNOPFE
Sector
Commodities - EnergyHealth
52-Week High
$60.13$28.56
52-Week Low
$27.20$23.60
Market Cap
$154.18B
Volume
29,869,932
Enterprise Value
$205.67B
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

United States Brent Oil Fund LP

BNO, a US-listed exchange-traded product tracking Brent crude oil futures, trades at $46.93, down 0.93% amid bearish technical signals. The overall technical outlook is bearish, with moving averages indicating selling pressure, while oscillators remain neutral. Recent news highlights Middle East tensions, particularly the deadlock over the Strait of Hormuz, influencing oil price volatility and investor sentiment.

The outlook for BNO is heavily tied to geopolitical developments and oil supply dynamics. Risks include prolonged Middle East instability and oil price corrections, but potential supply disruptions could offer upside. Investors should monitor OPEC decisions and US-Iran negotiations for directional cues, as these factors drive near-term performance.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About United States Brent Oil Fund LP

BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.

Read more on BNO

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE